Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous vs Intravenous Nivolumab in Advanced Clear Cell Renal Cell Carcinoma
NCT04810078Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of nivolumab in clear cell renal cell carcinoma (ccRCC), sponsored by Bristol Myers Squibb. Started May 2021; status: active, not recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04810078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810078.